|本期目录/Table of Contents|

[1]刘晓燕,车京津.ARNI逆转广泛前壁心肌梗死后左室重构1例报告[J].天津医科大学学报,2023,29(01):88-93.
点击复制

ARNI逆转广泛前壁心肌梗死后左室重构1例报告(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
29卷
期数:
2023年01期
页码:
88-93
栏目:
病例报告
出版日期:
2023-01-20

文章信息/Info

Title:
-
文章编号:
1006-8147(2023)01-0088-06
作者:
刘晓燕; 车京津
（天津医科大学第二医院心内科，天津300211）
Author(s):
-
关键词:
广泛性前壁心肌梗死; ARNI; 心力衰竭
Keywords:
-
分类号:
R541.4
DOI:
-
文献标志码:
B
摘要:
-
Abstract:
-

参考文献/References:

[1] MOTIWALA S R，GAGGIN H K. Biomarkers to predict reverse remodeling and myocardial recovery in hear failure[J]. J Curr Heart Fail Rep，2016，13（5）：207-218.
[2] 2020心肌梗死后心力衰竭防治专家共识[J].中国循环杂志，2020，35（12）：1166-1180.
[3] CURLEY D，LAVIN PLAZA B，SHAH A M，et al. Molecular imaging of cardiac remodelling after myocardial infarction[J]. Basic Res Cardiol，2018，113（2）：10.
[4] BHATT A S，AMBROSY A P，VELAZQUEZ E J. Adverse remodeling and reverse remodeling after myocardial infarction[J]. Curr Cardiol Rep，2017，19（8）：71.
[5] YANCY C W，JESSUP M，BOZKURT B，et al. ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA guideline for the management of heart failure：a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America[J]. Circulation，2017， 136（6）：e137-e161.
[6] HAJRA A，UJJAWAL A，SUD K，et al. Sacubitril/valsartan averts post-myocardial infarction ventricular remodeling and preserves heart function[J]. Int J Cardiol Heart Vasc，2019，22：218-219.
[7] VELAZQUEZ E J，MORROW D A，DEVORE A D，et al.Angiotensin-neprilysin inhibition in acute decompensated heart failure[J]. N Engl J Med，2019，380（6）：539-548.
[8] PASCUAL F D，WACHTER R，SENNI M，et al. Rationale and design of transition：a randomized trial of pre-discharge vs. post-discharge initiation of sacubitril/valsartan[J]. ESC Heart Fail，2018， 5（2）：327-336.
[9] POGGE E K，DAVIS L E. Evaluating the safety and tolerability of sacubitril/valsartan for hfref managed within a pharmacist clinic[J]. Am J Cardiovasc Drugs，2018，18（2）：143-151.
[10] MCMURRAY J J，PACKER M，DESAI A S，et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure：rationale for and design of the prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial （PARADIGM-HF）[J]. Eur J Heart Fail，2013，15（9）：1062-1073.
[11] SOLOMON S D，MCMURRAY J J，ANAND I S，et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction[J]. N Engl J Med，2019，381（17）：1609-1620.
[12] AL-MOHAMMAD A. Hydralazine and nitrates in the treatment of heart failure with reduced ejection fraction[J]. ESC Heart Fail，2019， 6（4）：878-883.
[13] ZIAEIAN B，FONAROW G C，HEIDENREICH P A. Clinical effectiveness of hydralazine-isosorbide dinitrate in african-american patients with heart failure[J]. JACC Heart Fail，2017，5（9）：632-639.
[14] BOHM M，SWEDBERG K，KOMAJDA M，et al. Heart rate as a risk factor in chronic heart failure（SHIFT）：the association between heart rate and outcomes in a randomised placebo-controlled trial[J]. Lancet，2010，376（9744）：886-894.
[15] TARDIF J C，O′MEARA E，KOMAJDA M，et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function：results from the shift echocardiography substudy[J]. Eur Heart J，2011，32（20）：2507-2515.
[16] PFEFFER M A，CLAGGETT B，ASSMANN S F，et al. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist（TOPCAT） trial[J]. Circulation，2015，131（1）：34-42.
[17] PITT B，PFEFFER M A，ASSMANN S F，et al. Spironolactone for heart failure with preserved ejection fraction[J]. N Engl J Med，2014， 370（15）：1383-1392.
[18] PONIKOWSKI P，VOORS A A ，ANKER S D，et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure：the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology （ESC）Developed with the special contribution of the Heart Failure Association（HFA） of the ESC[J]. Eur Heart J，2016，18（8）：891-975.
[19] PFEFFER M A，CLAGGETT B，LEWIS E F，et al. Paradise-mi investigators and committees. angiotensin receptor-neprilysin inhibition in acute myocardial infarction[J]. N Engl J Med，2021，385（20）： 1845-1855.
[20] KJELDSEN S E，VON LUEDER T G，SMISETH O A，et al. Medical therapies for heart failure with preserved ejection fraction[J]. Hypertension，2020，75（1）：23-32.

相似文献/References:

备注/Memo

备注/Memo:
基金项目: 苏州工业园区心馨心血管健康基金会（2022HX007）
作者简介:刘晓燕（1997-） ，女，硕士，研究方向：心血管病；通信作者：车京津，E-mail：jingjinche@163.com。
更新日期/Last Update: 2023-02-01